Cargando…
The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials. Despite its multiple biological functions, DMXAA has not been fully characterized...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605442/ https://www.ncbi.nlm.nih.gov/pubmed/23555875 http://dx.doi.org/10.1371/journal.pone.0060038 |
_version_ | 1782263892514177024 |
---|---|
author | Tang, Choon Kit Aoshi, Taiki Jounai, Nao Ito, Junichi Ohata, Keiichi Kobiyama, Kouji Dessailly, Benoit H. Kuroda, Etsushi Akira, Shizuo Mizuguchi, Kenji Coban, Cevayir Ishii, Ken J. |
author_facet | Tang, Choon Kit Aoshi, Taiki Jounai, Nao Ito, Junichi Ohata, Keiichi Kobiyama, Kouji Dessailly, Benoit H. Kuroda, Etsushi Akira, Shizuo Mizuguchi, Kenji Coban, Cevayir Ishii, Ken J. |
author_sort | Tang, Choon Kit |
collection | PubMed |
description | 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials. Despite its multiple biological functions, DMXAA has not been fully characterized for the potential application as a vaccine adjuvant. In this report, we show that DMXAA does act as an adjuvant due to its unique property as a soluble innate immune activator. Using OVA as a model antigen, DMXAA was demonstrated to improve on the antigen specific immune responses and induce a preferential Th2 (Type-2) response. The adjuvant effect was directly dependent on the IRF3-mediated production of type-I-interferon, but not IL-33. DMXAA could also enhance the immunogenicity of influenza split vaccine which led to significant increase in protective responses against live influenza virus challenge in mice compared to split vaccine alone. We propose that DMXAA can be used as an adjuvant that targets a specific innate immune signaling pathway via IRF3 for potential applications including vaccines against influenza which requires a high safety profile. |
format | Online Article Text |
id | pubmed-3605442 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36054422013-04-03 The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant Tang, Choon Kit Aoshi, Taiki Jounai, Nao Ito, Junichi Ohata, Keiichi Kobiyama, Kouji Dessailly, Benoit H. Kuroda, Etsushi Akira, Shizuo Mizuguchi, Kenji Coban, Cevayir Ishii, Ken J. PLoS One Research Article 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials. Despite its multiple biological functions, DMXAA has not been fully characterized for the potential application as a vaccine adjuvant. In this report, we show that DMXAA does act as an adjuvant due to its unique property as a soluble innate immune activator. Using OVA as a model antigen, DMXAA was demonstrated to improve on the antigen specific immune responses and induce a preferential Th2 (Type-2) response. The adjuvant effect was directly dependent on the IRF3-mediated production of type-I-interferon, but not IL-33. DMXAA could also enhance the immunogenicity of influenza split vaccine which led to significant increase in protective responses against live influenza virus challenge in mice compared to split vaccine alone. We propose that DMXAA can be used as an adjuvant that targets a specific innate immune signaling pathway via IRF3 for potential applications including vaccines against influenza which requires a high safety profile. Public Library of Science 2013-03-21 /pmc/articles/PMC3605442/ /pubmed/23555875 http://dx.doi.org/10.1371/journal.pone.0060038 Text en © 2013 Tang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Tang, Choon Kit Aoshi, Taiki Jounai, Nao Ito, Junichi Ohata, Keiichi Kobiyama, Kouji Dessailly, Benoit H. Kuroda, Etsushi Akira, Shizuo Mizuguchi, Kenji Coban, Cevayir Ishii, Ken J. The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant |
title | The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant |
title_full | The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant |
title_fullStr | The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant |
title_full_unstemmed | The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant |
title_short | The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant |
title_sort | chemotherapeutic agent dmxaa as a unique irf3-dependent type-2 vaccine adjuvant |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605442/ https://www.ncbi.nlm.nih.gov/pubmed/23555875 http://dx.doi.org/10.1371/journal.pone.0060038 |
work_keys_str_mv | AT tangchoonkit thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT aoshitaiki thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT jounainao thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT itojunichi thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT ohatakeiichi thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT kobiyamakouji thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT dessaillybenoith thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT kurodaetsushi thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT akirashizuo thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT mizuguchikenji thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT cobancevayir thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT ishiikenj thechemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT tangchoonkit chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT aoshitaiki chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT jounainao chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT itojunichi chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT ohatakeiichi chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT kobiyamakouji chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT dessaillybenoith chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT kurodaetsushi chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT akirashizuo chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT mizuguchikenji chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT cobancevayir chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant AT ishiikenj chemotherapeuticagentdmxaaasauniqueirf3dependenttype2vaccineadjuvant |